Sustagard Arthro, concentrate 200 mg/ml 2 ml 5 pcs

Pharmacotherapeutic group:

Tissue repair stimulator.

ATX code:

M01AX05.

Pharmacological properties

Pharmacodynamics. The drug has stimulating regeneration of cartilage tissue, anabolic, anti-catabolic, chondroprotective, anti-inflammatory, analgesic action. Glucosamine sulfate, the active ingredient of the drug SUSTAGARD® ARTRO, is a salt of the natural aminonosaccharide glucosamine, which is physiologically present in the body. Glucosamine stimulates the synthesis of proteoglycans (glycosaminoglycans and hyaluronic acid) of synovial fluid by chondrocytes; it inhibits enzymes (collagenase, phospholipase A2, etc.) that cause destruction of synovial fluid.), causing destruction of cartilage tissue; prevents the formation of superoxide radicals, inhibits the activity of lysosomal enzymes; initiates the process of sulfur fixation in the synthesis of chondroitinic acid and promotes normal calcium deposition in bone tissue; prevents the damaging effect of corticosteroids on chondrocytes and disruption of glycosaminoglycan synthesis induced by non-steroidal anti-inflammatory drugs.

Sulfogroups are also involved in glycosaminoglycan synthesis and cartilage metabolism, and side-chain sulfoesters in proteoglycans, contributing to water retention – in maintaining cartilage matrix elasticity.

Glucosamine sulfate stops the destruction of cartilage and reduces symptoms in osteoarthritis. A reduction in clinical symptoms is usually seen within 2 weeks of starting treatment with continued clinical improvement for up to 8 weeks after discontinuation of the drug.

Pharmacokinetics. After intramuscular administration glucosamine sulfate rapidly passes through biological barriers and penetrates into tissues, mainly articular cartilage. The half-life of T1/2 is about 60 h, it is excreted mainly by the kidneys.

Indications

Primary and secondary osteoarthrosis, osteochondrosis, spondyloarthrosis.

Pharmacological effect

Pharmacotherapeutic group:

tissue repair stimulator.

ATX Code:

M01AX05.

Pharmacological properties

Pharmacodynamics. The drug has stimulating regeneration of cartilage tissue, anabolic, anti-catabolic, chondroprotective, anti-inflammatory, analgesic effects. Glucosamine sulfate, the active component of SUSTAGARD® ARTRO, is a salt of the natural aminomonosaccharide glucosamine, which is physiologically found in the body. Glucosamine stimulates the synthesis of proteoglycans (glycosaminoglycans and hyaluronic acid) in synovial fluid by chondrocytes; inhibits enzymes (collagenase, phospholipase A2, etc.) that cause destruction of cartilage tissue; prevents the formation of superoxide radicals, suppresses the activity of lysosomal enzymes; initiates the process of sulfur fixation in the synthesis of chondroitinsulfuric acid and promotes normal calcium deposition in bone tissue; prevents the damaging effect of corticosteroids on chondrocytes and the disruption of glycosaminoglycan synthesis induced by non-steroidal anti-inflammatory drugs.

Sulfo groups also take part in the synthesis of glycosaminoglycans and the metabolism of cartilage tissue, and sulfoesters of side chains in the composition of proteoglycans, promoting water retention – in maintaining the elasticity of the cartilage matrix.

Glucosamine sulfate stops the destruction of cartilage and reduces symptoms of osteoarthritis. A decrease in clinical symptoms usually appears 2 weeks after the start of treatment, with clinical improvement continuing for 8 weeks after discontinuation of the drug.

Pharmacokinetics. After intramuscular administration of glucosamine sulfate, it quickly passes through biological barriers and penetrates tissue, mainly articular cartilage. The half-life T1/2 is about 60 hours, excreted mainly by the kidneys.

Special instructions

SUSTAGARD® ARTHRO should be administered with caution to patients with impaired glucose tolerance. Use with caution when treating patients with bronchial asthma.
One dose of the drug contains 40.8 mg of sodium. This should be taken into account when prescribing to patients who are indicated for a strict salt-free diet.
Due to the fact that the injection form of the drug contains the excipient lidocaine, before using it it is necessary to conduct a skin test to determine individual sensitivity to the drug, which may be indicated by swelling and redness of the injection site.

Impact on the ability to drive vehicles and machinery
The effect of glucosamine on the ability to drive vehicles and machines has not been examined. Please note that the composition contains lidocaine, which may have a temporary effect on motor ability and coordination. During the treatment period, care must be taken when driving vehicles and engaging in other potentially hazardous activities.

Active ingredient

Glucosamine

Composition

Ampoule A. One ampoule (2 ml) contains:

active ingredient: glucosamine sulfate sodium chloride (in terms of dry matter) – 502.5 mg (contains glucosamine sulfate – 400 mg, sodium chloride – 102.5 mg).

excipients: lidocaine hydrochloride – 10.0 mg, sodium disulfite – 2.0 mg, concentrated hydrochloric acid – up to pH 2.0-3.0, water for injection – up to 2 ml.

Ampoule B (solvent). One ampoule (1 ml) contains: diethanolamine – 24.0 mg, water for injection – up to 1 ml.

Contraindications

Hypersensitivity to glucosamine, lidocaine and other components of the drug SUSTAGARD® ARTRO. Due to the content of lidocaine: cardiac conduction disorders, acute heart failure, history of epileptiform seizures, severe dysfunction of the liver and kidneys; period of pregnancy and breastfeeding, childhood and adolescence up to 18 years.

With caution

In patients with chronic heart failure and arterial hypotension, the drug should be used with caution.

If you are intolerant to seafood (shrimp, shellfish), the likelihood of developing allergic reactions to the drug increases.

The safety of using anesthetics of the lidocaine group is questionable in patients prone to malignant hyperthermia, so in such cases their use should be avoided. Particular caution should be exercised when using the drug in patients with circulatory insufficiency, arterial hypotension, and impaired liver and/or kidney function. Caution should be exercised when prescribing lidocaine to elderly patients, patients with epilepsy, cardiac conduction disorders, and respiratory failure.

Side Effects

From the digestive system: flatulence, diarrhea, constipation.
Allergic reactions: urticaria, itching.
Local reactions: slight burning sensation (disappears with the development of an anesthetic effect within 1 minute), thrombophlebitis.
Due to the lidocaine included in the drug, adverse reactions characteristic of this component in the digestive system are possible: nausea, vomiting; from the nervous system: numbness of the tongue and oral mucosa, drowsiness, diplopia, headache, dizziness, tremor, euphoria, disorientation; from the cardiovascular system: cardiac conduction disorders; allergic reactions: swelling, anaphylactic shock.
The sodium disulfite contained in the drug can, in rare cases, cause severe hypersensitivity reactions and bronchospasm.

Overdose

No cases of overdose have been identified.
The drug contains the excipient lidocaine hydrochloride. The first symptoms of an overdose of lidocaine hydrochloride from the central nervous system may be: numbness of the tongue and lips, agitation, anxiety, tinnitus, dizziness, blurred vision, tremor, depression, drowsiness.
It is necessary to monitor the patient’s cardiovascular and respiratory functions. A change in these parameters may indicate an overdose of the drug, so the patient should immediately be provided with access to oxygen. All complications require symptomatic treatment.

Storage conditions

Store in a dry place, protected from light and out of reach of children, at a temperature not exceeding +25°C.

Shelf life

2 years.

Manufacturer

PharmFirma Sotex, Russia